Skip to main content
×
×
Home

Tardive dyskinesia update: treatment and management

  • David Cunningham Owens (a1)
Summary

The development of rational treatments for tardive dyskinesia has been held back by limitations to our understanding of its aetiology, which even now does not extend far beyond its association with centrally acting dopamine-blocking drugs. This article reviews briefly the major aetiological theories and addresses general management and specific treatment options. Primary prevention and early recognition remain the crucial management issues because, once the condition is established, there are no satisfactory treatments. The article considers two newly developed drugs, valbenazine and deutetrabenazine, in some detail as, although they are not yet licensed in Europe, they have largely been responsible for an upsurge in interest in tardive dyskinesia in the North American literature and are likely to be widely promoted in the future. Although possessed of undoubted benefits, the evidence suggests that these represent small steps rather than large leaps forward in treatment.

LEARNING OBJECTIVES

  • Be able to discuss the major aetiological theories on the causation of a common, and sometimes serious, adverse action of antidopaminergic drugs
  • Understand general management and specific treatment options
  • Understand the pharmacology and efficacy of two drugs recently approved by the FDA for the treatment of tardive dyskinesia

DECLARATION OF INTEREST

D.C.O. is psychiatric commissioner on the Commission on Human Medicines, the UK drug regulator, and chair of its expert advisory group on CNS drugs. He is also a member of the psychiatry Scientific Advisory Group of the European Medicines Agency.

Copyright
Corresponding author
Correspondence Professor David Cunningham Owens, University Division of Psychiatry, Kennedy Tower, Royal Edinburgh Hospital, Morningside Terrace, Edinburgh EH10 5HF, UK. Email: david.owens@ed.ac.uk
Footnotes
Hide All

For a companion article, see Owens DC (2018) Tardive dyskinesia: an update 1: the syndrome. BJP Advances, XXX: XX–XX.

Footnotes
References
Hide All
Adler, LA, Edson, R, Lavori, P, et al. (1998) Long-term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry, 43: 868–72.
Ahmed, S, Chengappa, KN, Naidu, VR, et al. (1998) Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. Journal of Clinical Psychiatry, 59: 472–7.
Alabed, S, Latifeh, Y, Mohammad, HA, et al. (2011) Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 4: CD000203 (doi: 10.1002/14651858.CD000203.pub3).
Anderson, KE, Stamler, D, David, MD, et al. (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Psychiatry, 4: 595604.
Arbuthnott, G, Garcia-Munoz, M (2010) Neuropharmacology. In Companion to Psychiatric Studies (eds Johnstone, EC, Owens, DGC, Lawrie, SM, et al. ): 4576. Churchill Livingstone.
Bergman, H, Walker, D-M, Nikolakopoulou, A, et al. (2017) Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technology Assessment, 21(43): 1218.
Bergman, H, Rathbone, J, Agarwal, V, et al. (2018) Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews, 2: CD000459 (doi: 10.1002/14651858.CD000459.pub3).
Bhidayasiri, R, Jitkritsadakul, O, Friedman, JH, et al. (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. Journal of Neurological Sciences, 389: 6775.
Bishnoi, M, Chopra, K, Kilkarni, SK (2007) Protective effect of rutin, a polyphenolic flavinoid, against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundamental Clinical Pharmacology, 21: 521–9.
Cadet, JL, Lohr, JB, Jeste, DV (1986) Free radicals and tardive dyskinesia. Trends in Neurosciences, 9: 107–8.
Calabresi, P, Pisani, A, Rothwell, J, et al. (2016) Hyperkinetic disorders and loss of synaptic downscaling. Nature Neuroscience, 19: 868–75.
Carbon, M, Hsieh, C-H, Kane, JM, et al. (2017) Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. Journal of Clinical Psychiatry, 78: e26478.
Caroff, SN, Walker, P, Campbell, C, et al. (2007) Treatment of tardive dyskinesia with galantamine: a randomised controlled cross-over trial. Journal of Clinical Psychiatry, 68: 410–5.
Citrome, L, Jaffe, A, Levine, J, et al. (2005) Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Journal of Clinical Psychiatry, 66: 1512–6.
Citrome, L, Kantrowitz, JT (2009) Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Reviews in Neurotherapy, 9: 1045–58.
Citrome, L (2017a) Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 71: e12964.
Citrome, L (2017b) Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 71: e13030.
Davis, MC, Miller, BJ, Kalsi, JK, et al. (2017) Efficient trial design – FDA approval of valbenazine for tardive dyskinesia. New England Journal of Medicine, 376: 2503–6.
Elkashef, AM, Wyatt, RJ (1999) Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophrenia Bulletin, 25: 731–40.
Fernandez, HH, Factor, SA, Hauser, RA, et al. (2017) Randomised controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology, 88: 2003–10.
Fibiger, HC, Lloyd, KG (1984) Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends in Neurosciences, 7: 462–4.
Fischer-Barnicol, D, Lanquillon, S, Haen, E, et al. (2008) Typical and atypical antipsychotics – the misleading dichotomy. Neuropsychobiology, 57: 80–7.
Gerlach, J (1981) Prevention/treatment of tardive dyskinesia. Acta Psychiatrica Scandinavica Supplementum, 291: 117–28.
Grigoriadis, DE, Smith, E, Hoare, SR, et al. (2017) Pharmacologic characterisation of valbenazine (NBI-98854) and its metabolites. Journal of Pharmacology and Experimental Therapeutics, 361: 454–61.
Guay, DRP (2010) Tetrabenzine: a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. American Journal of Geriatric Pharmacotherapy, 8: 331–72.
Guy, W (1976) ECDEU Assessment Manual for Psychopharmacology (publication ADM 76 – 338). US Department of Health, Education and Welfare.
Hatcher-Martin, JM, Armstrong, KA, Scorr, LM, et al. (2016) Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism and Related Disorders, 32: 124–6.
Hauser, RA, Factor, SA, Marder, SR, et al. (2017) KINECT 3: a Phase 3 randomised, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry, 174: 476–84.
Hazari, N, Kate, N, Grover, S (2013) Clozapine and tardive movement disorders: a review. Asian Journal of Psychiatry, 6: 439–51.
Howes, OD, Kapur, S (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophrenia Bulletin, 35: 549–62.
Jankovic, J (2009) Treatment of hyperkinetic movement disorders. Lancet Neurology, 8: 844–56.
Jankovic, J (2017) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon, 147: 84–8.
Jeste, DV, Wyatt, RJ (1981) Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity? Journal of Clinical Psychiatry, 42: 455–7.
Jeste, DV, Lohr, JB, Clark, K, et al. (1988) Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology, 8(suppl 4): 38S48S.
Jones, PB, Barnes, TR, Davies, L, et al. (2006) Randomised controlled trial of the effect on Quality of Life of second- versus first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63: 1079–87.
Karson, CN, Jeste, DV, LeWitt, PA, et al. (1983) A comparison of two iatrogenic dyskinesias. American Journal of Psychiatry, 140: 1504–6.
Li, YC, Kavalali, ET (2017) Synaptic vesicle-recycling machinery components as potential therapeutic targets. Pharmacological Reviews, 69: 141–60.
Lieberman, JA, Salz, BL, Johns, CA, et al. (1991) The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158: 503–10.
Lieberman, JA, Stroup, TS, McEvoy, JP, et al. (2005) Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine, 353: 1209–23.
Lim, SAO, Kang, UJ, McGehee, DS (2014) Striatal cholinergic interneuron regulation and circuit effects. Frontiers in Synaptic Neuroscience, 6: 123.
Lister, J, Nobrega, JN, Fletcher, PJ (2014) Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence from antioxidant-based prevention strategies. Psychopharmacology, 231: 2237–49.
Lister, J, Andreazza, AC, Navaid, B, et al. (2017) Lipoic acid and haloperidol-induced vacuous chewing movements: implications for prophylactic antioxidant use in tardive dyskinesia. Progress in Neuropsychopharmacology and Biological Psychiatry, 72: 23–9.
Lohr, JB (1991) Oxygen radicals and neuropsychiatric illness: some speculations. Archives of General Psychiatry, 48: 1097–106.
Louza, MR, Bassitt, DP (2005) Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up. Journal of Clinical Psychopharmacology, 25: 180–2.
Miller, R, Chouinard, G (1993) Loss of striatal cholinergic neurones as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry, 34: 713–38.
O'Brien, CF, Jiminez, R, Hauser, RA, et al. (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Movement Disorders, 30: 1681–7.
Owens, DGC, Finlayson, A, Mercer, G, et al. (1997) The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia. Journal of Psychopharmacology, 11: 357–60.
Owens, DGC (2014) A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs (2nd edn). Cambridge University Press.
Owens, DGC (2018) Tardive dyskinesia: an update. 1. The syndrome. BJPsych Advances, in press.
Pouclet-Courtemanche, H, Rouand, T, Thobois, S, et al. (2016) Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology, 86: 651–9.
Rodrigues, FB, Duarte, GS, Costa, J, et al. (2017) Meta-research metrics matter: letter regarding article ‘indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. Journal of Clinical Movement Disorders, 4: 19.
Shi, J, Tan, YL, Wang, ZR, et al. (2016) Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewing movement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. Pharmacology, Biochemistry and Behaviour, 148: 53–8.
Soares-Weiser, K, Maayan, N, McGrath, J (2011) Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 2: CD000209 (doi: 10.1002/14651858.CD000209.pub.2).
Sun, CH, Zheng, W, Yang, XH, et al. (2017) Adjunctive melatonin for tardive dyskinesia in patients with schizophrenia: a meta-analysis. Shanghai Archives of Psychiatry, 29: 129–36.
Tammenmaa-Aho, I, Asher, R, Soares-Weiser, K, et al. (2018) Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 3: CD000207 (doi: 10.1002/14651858.CD000207.pub2).
Teo, JT, Edwards, MJ, Bhatia, K (2012) Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Movement Disorders, 27: 1205–15.
Thaakur, S, Himabindhu, G (2009) Effect of alpha lipoic acid on tardive dyskinesia and oxidative stress induced by haloperidol in rats. Journal of Neural Transmission, 116: 807–14.
Thaker, GK, Nguyen, JA, Strauss, ME, et al. (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. American Journal of Psychiatry, 147: 445–51.
Verdoux, H, Tournier, M, Begaud, B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica, 121: 410.
Waddington, J (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology, 101: 431–7.
Zhang, WF, Tan, YL, Zhang, XY, et al. (2011) Extract of Gingko Biloba treatment for tardive dyskinesia in schizophrenia: a randomised, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 72: 615–21.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 2056-4678
  • EISSN: 2056-4686
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Tardive dyskinesia update: treatment and management

  • David Cunningham Owens (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *